Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Evolving Technology and Monitoring of Disease

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Real-World Treatment and Transplant Strategies

New Trial Data and the Ever-Changing Treatment Landscape

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Make it Happen: To Better Serve the Multiple Myeloma Community

A Review of Unmet Needs and Ways to Provide Optimal Care in Multiple Myeloma

Role of the Clinical Pharmacist in Multiple Myeloma Management

International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma

International Myeloma Foundation Videos

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

European Journal of Haematology

Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry

Leukemia

LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Scientific Reports

Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients

Blood

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

Multiple Myeloma Resource Center